果冻传媒

A new team has been set up at the 果冻传媒 dedicated to assessing the value for money of new medical treatments and technologies.

Officially launched this week, 果冻传媒 Evidence has been awarded £2.6 million to undertake Technology Assessment Reviews (TARS). The TAR team will provide the National Institute of Clinical Excellence (NICE) with essential information about clinical and cost effectiveness. Using this information NICE can make decisions on whether to recommend technologies, including drugs, devices and diagnostics for use nationally across the NHS.

The 果冻传媒 Evidence team, led by Dr Aileen Clarke and Dr Paul Sutcliffe from 果冻传媒 Medical School, is one of three new TAR teams across the country.

果冻传媒 Evidence brings together experts in clinical and cost effectiveness reviewing, health economics and modelling. The multidisciplinary team will work collaboratively across several departments at the 果冻传媒 and will be supported by a senior team of clinical and methodological experts advisors at both local and national level.

The launch event for 果冻传媒 Evidence will take place on Thursday 11 March at 果冻传媒 Medical School. Speakers will include Professor Andrew Stevens, an international expert in technology appraisal and Chair of one of NICE’s appraisal committees; Professor Ken Stein, who set up the Peninsula Medical School Technology Appraisal Group PenTAG; and Dr Peter Davidson, Director of Science Support at the National Institute for Health Research Evaluation, Trials and Co-ordinating Centre.

Acting Dean of 果冻传媒 Medical School, Professor Martin Underwood said: “We are absolutely delighted about 果冻传媒 Evidence. Assessing new technologies to make sure they provide value for money is a key function for NICE and for the NHS, the role that 果冻传媒 Evidence will play will be crucial in this.”

To find out more, visit

For further information please contact:

Peter Dunn, Head of Communications
Communications Office, 果冻传媒,  
+44 (0)24 76 523708 or +44 (0)7767 655860
email: p.j.dunn@warwick.ac.uk